In line with our results, Koscielska-Kasprzak et al. investigated the long-term kidney transplant recipients (stable = 44 and chronic allograft dysfunction = 22) and reported that serum level of BAFF could not discriminate chronic allograft dysfunction patients from stable patients [35]. This evidence concerns the gene TNFSF13B and medical procedure.